Find your next paid study

Memorial Sloan Kettering Cancer CenterNCT06021626

Advanced Solid TumorNon-Small Cell Lung CancerColorectal Neoplasms+1 more

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Enrichment, and Dose-Expansion Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BLU-924 (SAR449336) as Monotherapy and Combination Therapy in Participants With Advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Harboring KRAS Mutations

A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in particip…

Blueprint Medicines CorporationNCT07629960

Observational

Strengthening Awareness and Community Resources for Early Detection of Lung Cancer Through Navigation Guided Screening Trial (SACRED LUNGS Aims 1.2-3)

This clinical trial studies whether tailored patient navigation (PN) works to improve the uptake of lung cancer screening (LCS) in tribal communities in wester…

Lung Carcinoma

Fred Hutchinson Cancer CenterNCT07176000

Observational

Impact of Routine Electronic Patient-Reported Outcome (ePRO)Symptom Monitoring During Neoadjuvant Therapy in Patients withPancreatic Adenocarcinoma on Patient Experience and ClinicalOutcomes: A Prospective Pre-Post Implementation Study

To learn if routine symptom monitoring using questionnaires during chemotherapy and/or radiation therapy in patients with PDAC improves patient health-related …

ePROSymptom MonitoringNeoadjuvant Therapy+2 more

M.D. Anderson Cancer CenterNCT07829471

Observational

Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer (Wisdom Study)

Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics…

Breast Cancer ScreeningBreast Carcinoma in SituBreast Cancer

University of California, San FranciscoNCT02620852

~$10 – $5,625

Non Small Cell Lung CancerEsophageal CancerSmall Cell Lung Cancer+7 more

A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung C…

SystImmune Inc.NCT05983432

Phase 2

A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

The goal of this clinical study is to learn more about the study drug, Denikitug (DEN, GS-1811), to evaluate the efficacy and safety of Denikitug Monotherapy a…

HER2-negativeGastroesophageal JunctionEsophageal Adenocarcinoma+1 more

Gilead SciencesNCT07546812

~$10 – $7,500

Phase 3

Providing Nicotine Replacement Therapy to Enhance the Efficacy of a Smoking Cessation Smartphone App for Hispanic Adults

This phase III trial compares a smartphone application with or without nicotine replacement therapy in improving smoking cessation among Hispanic adults who wo…

Cigarette Smoking-Related Carcinoma

Fred Hutchinson Cancer CenterNCT06811038

Phase 2

A Phase II Sequential Window of Opportunity Trial of Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

Background: Squamous cell carcinoma is a type of cancer that can cause tumors on the head and neck (HNSCC). Even with treatment, less than 50% of people with …

Stage II Squamous Cell Carcinoma of the Head and NeckStage III Squamous Cell Carcinoma of the Head and NeckStage IV Squamous Cell Carcinoma of the Head and Neck

National Cancer Institute (NCI)NCT06161545

~$10 – $5,625

Phase 2

A Phase II Randomized Trial of Intermittent Androgen Deprivation Therapy Alone or Combined With [177Lu]Lu-PSMA-617, With or Without Abiraterone and Prednisone, in Patients With Low-Volume Metastatic Hormone-Sensitive Prostate Cancer

This phase II trial tests leuprolide acetate alone versus in combination with 177Lu-PSMA-617, with or without abiraterone acetate and prednisone, for the treat…

Recurrent Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8Castration-Sensitive Prostate Cancer+9 more

Mayo ClinicNCT07650240

Clear Cell Renal Cell Carcinoma

An Open-Label, Multicenter, Phase 1a/1b, Dose Escalation/Dose Expansion Clinical Trial of Theranostic Pair PD-32766D, a 64Cu-Labeled Peptide and PD-32766T, an 225Ac-Labeled Peptide Targeting Carbonic Anhydrase IX in Adult Participants With Relapsed or Refractory Clear Cell Renal Cell Carcinoma Who Have Progressed From or Could Not be Administered Due to Medical Unsuitability or Limited Access to All Standard of Care Therapies

This is an open-label, multicenter, Phase 1a/1b study evaluating the theranostic pair 64Cu-PD-32766 Injection (PD-32766D) and 225Ac-PD-32766 Injection (PD-3276…

PeptiDream Inc.NCT07688187

Advanced or Metastatic Solid TumorsTriple Negative Breast Cancer (TNBC)HR+ Breast Cancer+8 more

A Phase 1 Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SHY-ONC6 in Participants With Advanced or Metastatic Solid Tumors

This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity o…